Baidu
map

消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

中国炎症性肠病治疗药物监测专家共识意见

2018-12-10 中华医学会消化病学分会炎症性肠病学组 中华消化杂志.2018, 38(11):721-727.

炎症性肠病治疗药物监测

生物制剂和免疫调节剂是诱导和维持IBD 疾病缓解的重要药物.合适的药物浓度对提高疗效和减少不良反应具有重要临床意义.在IBD治疗过程中 进 行 治 疗 药 物 监 测 ( therapeutic drug monitoring ,TDM ) ,可以最大限度优化药物使用 ,更好地指导治疗策略的选择.2017年美国胃肠病学会 ( American Gastroenterological Associa

中文标题：

中国炎症性肠病治疗药物监测专家共识意见

发布机构：

中华医学会消化病学分会炎症性肠病学组

发布日期：

2018-12-10

简要介绍：

生物制剂和免疫调节剂是诱导和维持IBD 疾病缓解的重要药物.合适的药物浓度对提高疗效和减少不良反应具有重要临床意义.在IBD治疗过程中 进 行 治 疗 药 物 监 测 ( therapeutic drug monitoring ,TDM ) ,可以最大限度优化药物使用 ,更好地指导治疗策略的选择.2017年美国胃肠病学会 ( American Gastroenterological Association , AGA )发布了IBD的 TDM 共识 ,澳大利亚也在同年发表了抗 TNF-α制剂的 TDM 共识.近年来我国IBD患者逐渐增多 ,如何更好地结合我国实际情况进行优化治疗以达到最佳的治疗效果 ,这已经成为临床医师必须面对的常见问题.鉴于此,中华医学会消化病学分会炎症性肠病学组组织我国 IBD领域部分专家 ,于2018年8月24日在西安召开了IBD的TDM 研讨会,回顾国际和国内有关IBD的TDM 相关资料 ,达成以下我国IBD的TDM共识意见. 

拓展指南：与炎症性肠病相关指南：

下载附件：
点击下载

(因为版权问题，不支持下载)

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1230493, encodeId=d1a31230493a3, content=还是抗炎治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0158135594, createdName=ms3000001902565087, createdTime=Mon Jul 04 15:45:58 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976150, encodeId=96e99e61508d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210623/49965d9363c8465cbebfe436532e8aaa/1ad60eb0fe5a4201a49971544350f958.jpg, createdBy=333b5531849, createdName=LL求知的小罗罗, createdTime=Wed Jun 23 10:58:18 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361060, encodeId=d475361060e9, content=很好。感谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:40:19 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2022-07-04 ms3000001902565087

    还是抗炎治疗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1230493, encodeId=d1a31230493a3, content=还是抗炎治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0158135594, createdName=ms3000001902565087, createdTime=Mon Jul 04 15:45:58 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976150, encodeId=96e99e61508d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210623/49965d9363c8465cbebfe436532e8aaa/1ad60eb0fe5a4201a49971544350f958.jpg, createdBy=333b5531849, createdName=LL求知的小罗罗, createdTime=Wed Jun 23 10:58:18 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361060, encodeId=d475361060e9, content=很好。感谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:40:19 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2021-06-23 LL求知的小罗罗

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1230493, encodeId=d1a31230493a3, content=还是抗炎治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0158135594, createdName=ms3000001902565087, createdTime=Mon Jul 04 15:45:58 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976150, encodeId=96e99e61508d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210623/49965d9363c8465cbebfe436532e8aaa/1ad60eb0fe5a4201a49971544350f958.jpg, createdBy=333b5531849, createdName=LL求知的小罗罗, createdTime=Wed Jun 23 10:58:18 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361060, encodeId=d475361060e9, content=很好。感谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:40:19 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-02-20 天天作西

    很好。感谢分享。

    0

相关指南

2018 ACPGBI共识指南：手术治疗炎症性肠病

大不列颠及爱尔兰肛肠协会(ACPGBI,Association of Coloproctology of Great Britain and Ireland) · 2018-12-02

炎症性肠病诊断与治疗的共识意见（2018年•北京）

中华医学会消化病学分会炎症性肠病学组 · 2018-09-20

2018 ESPGHAN立场声明：生物仿制药在儿童炎症性肠病患者中的应用（更新版）

欧洲儿科胃肠病学、肝病学和营养协会(ESPGHAN,European Society for Paediatric Gastroenterology, Hepatology, and Nutrition) · 2018-08-30

2018 ECCO/ESGAR指南：炎症性肠病的诊断评估

欧洲胃肠道和腹部放射学会(ESGAR,European Society of Gastrointestinal and Abdominal Radiology) · 2018-08-23

2018 NASPGHAN临床报告：确保儿童炎症性肠病非住院患者生物制剂输注质量

北美小儿胃肠病、肝脏病和营养学会(NASPGHAN,North American society for pediatric gastroenterology,Hepatology,and nutrition) · 2018-04-10

2018 ACG临床指南：成人克罗恩病的管理

美国胃肠病学院(ACG,American College of Gastroenterology) · 2018-03-27

Baidu
map
Baidu
map
Baidu
map